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Plant-Made Vaccine Antigens and Biopharmaceuticals
Abstract
Plant cells are ideal bioreactors for the production and oral delivery of vaccines and biopharmaceuticals,
eliminating the need for expensive fermentation, purification, cold storage, transportation and sterile
delivery. Plant-made vaccines have been developed for two decades but none has advanced beyond
Phase I. However, two plant-made biopharmaceuticals are now advancing through Phase II and Phase III
human clinical trials. In this review, we evaluate the advantages and disadvantages of different plant
expression systems (stable nuclear and chloroplast or transient viral) and their current limitations or
challenges. We provide suggestions for advancing this valuable concept for clinical applications and
conclude that greater research emphasis is needed on large scale production, purification, functional
characterization, oral delivery and preclinical evaluation.
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Plant cells are ideal bioreactors for the production and oral delivery of vaccines and
biopharmaceuticals, eliminating the need for expensive fermentation, purification, cold storage,
transportation and sterile delivery. Plant-made vaccines have been developed for two decades but
none has advanced beyond Phase I. However, two plant-made biopharmaceuticals are now advancing
through Phase II and Phase III human clinical trials. In this review, we evaluate the advantages and
disadvantages of different plant expression systems (stable nuclear and chloroplast or transient viral)
and their current limitations or challenges. We provide suggestions for advancing this valuable
concept for clinical applications and conclude that greater research emphasis is needed on large scale
production, purification, functional characterization, oral delivery and preclinical evaluation.

Need for a new platform for production of therapeutic proteins
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Approximately 15 million (>25%) of 57 million deaths per year worldwide are estimated to
be related directly to infectious diseases [1]. Vaccination is considered to be the most efficient
and cost-effective means for health intervention to combat infectious diseases. However, the
high cost of vaccination makes it unaffordable for most people living in developing countries,
as the daily average income for nearly one billion people is <US$1. A 14-fold increase in the
cost of vaccines over the past decade [2] makes it necessary to investigate alternate strategies
for their production and delivery. Also, with an emphasis on safety, there has been an increasing
shift towards the development of subunit vaccines (that use one or two proteins instead of
avirulent or killed pathogen strains), with reliance on recombinant expression systems. The
high cost of current vaccines and biopharmaceuticals is largely due to their complex production
and delivery methods, including the significant costs of fermentation and purification systems
and additional expenses associated with adjuvant, cold storage, transportation and sterile
delivery. No viable alternative to fermentation technology has yet emerged for their mass
production, a void that could be addressed through the use of plants as bioreactors for the
production and oral delivery of therapeutic proteins. In this review, we evaluate the advantages
and disadvantages of different plant expression systems (stable nuclear, transient viral and
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stable chloroplast), and their current limitations or challenges ahead. We further discuss
directions for advancing this valuable concept for clinical applications.
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Plant-made therapeutic proteins – current status and challenges ahead
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Plant-made vaccines and therapeutics refer to protein products with clinical or veterinary
applications produced in recombinant plant systems. These systems can be broadly divided
into those using nuclear transgenic technology, chloroplast transplastomic technology and
plant viral technology (Figure 1). In all cases, the antigens or therapeutics are expressed in
plant tissues, from which they can be either purified, or the plant tissue can be processed into
a form that can be applied topically or, more uniquely, orally. The major advantage of plant
expression systems over other vaccine production systems is reduced manufacturing cost.
Fermenters and bioreactors can be replaced with contained plant growth rooms or greenhouses
or plants can be grown in the field with appropriate biological containment of foreign genes,
such as maternal inheritance or male sterility, or expression in vegetative tissues with harvest
before appearance of any reproductive structure. This should lead to reduced upstream facility
costs. In the case of oral plant-produced vaccines and therapeutics, downstream processing
costs are also reduced. Instead of protein purification targeting up to ~ 99% purity, plant tissues
can be inexpensively processed for oral delivery. The relevant technology has already been
developed in the food and feed industries, and can be adapted for plant-produced therapeutic
proteins.
As with other eukaryotic systems, plant-produced vaccines enable the introduction of posttranslational modifications. Proper folding and disulfide bond formation occur in chloroplasts
[3] or the endoplasmic reticulum [4]. Proper lipid modifications of vaccine antigens have also
been observed in chloroplasts [5]. Therapeutic proteins are not glycosylated in chloroplasts but
are glycosylated when targeted to the endoplasmic reticulum, although glycosylation patterns
are not identical to mammalian systems. Although numerous therapeutic proteins have been
expressed in plant cells (Tables 1-3, Online Supplementary Tables S1-S3), several challenges
remain. Transgene silencing in nuclear transgenic plants requires further investigation and
improvement. More tools are needed for transgene containment to facilitate field production
of vaccines or biopharmaceuticals, when expressed via the nuclear genome. More generally,
expression levels are target dependent, and are a challenge for all recombinant systems.

NIH-PA Author Manuscript

Many functional assays (such as host cell protein) have not yet been developed for injectable
products. Despite active research, there is limited published work on highly purified proteins
and characterization of contaminants. It is well known that expression level varies depending
on the developmental stage of leaves, the time of day and the regulatory sequences used,
underscoring the importance of the developmental stage of the plants and the time of harvest.
Most importantly, achieving consistency of transgene expression in different batches is an
important challenge. Therefore, harvested leaves should be homogenized and level of
therapeutic protein must be determined for each harvested batch. There are limited studies on
determination of stability of therapeutic proteins after harvest, processing and storage. Removal
of Agrobacteria after vacuum infiltration of viral vectors is yet another challenge. All the above
concerns need to be addressed with careful and reproducible investigations.
The current focus for most groups is on purified antigens prepared from plants grown in
contained conditions. This avoids environmental release and enables controlled plant growth
but decreases the cost advantage versus field-grown plants because construction of greenhouses
or growth rooms to meet regulatory approval is relatively expensive. In the case of oral delivery,
moving forward on the most promising veterinary candidates should lay the foundation for
human vaccines. Determining a regulatory pathway for oral products is a major hurdle, given
the limited resources of the prominent research groups in the field. Purified vaccines and
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therapeutic proteins might follow a similar regulatory path to recombinant proteins produced
in other systems, with the focus on stability, potency and efficacy of the purified product. As
with other purified protein subunit vaccines, adjuvants are needed and must be developed
alongside target antigens.
Over the past two decades, vaccine antigens expressed via the plant nuclear genome have
elicited appropriate immunoglobulin responses and have conferred protection upon oral
delivery [6,7] but no transgenic plant-based vaccine has yet moved beyond a Phase I clinical
trial [7]. However, at least two therapeutics developed by Biolex (http://www.biolex.com) and
Protalix (http://www.protalix.com) are moving through Phase II and Phase III [8-10].

Stably integrated nuclear transgenes

NIH-PA Author Manuscript

The earliest work using plants for the recombinant expression of vaccine antigens was
performed using stable transformation of the nuclear genome of tobacco (Nicotiana
tobacum) [11]. The ease of nuclear transgene methodology, started by Agrobacteriummediated delivery of DNA, facilitated this approach, which was the dominant strategy for
several years. Advantages include the ability to scale up production of large amounts of vaccine
antigens from transgenic seed stocks, and the possibility of expression in fruits or other edible
plant organs, enabling oral delivery of minimally processed materials. However, stably
integrated nuclear transgenes typically yield relatively low levels of expression (<1% total
soluble protein, TSP, Online Supplementary Table S1), which can vary plant to plant and
generation to generation, probably owing to gene silencing or position effect [12].

NIH-PA Author Manuscript

Many different vaccine antigens have been produced in various plant species, including
tobacco and edible plants (e.g. Solanum tuberosum, Solanum lycopersicum, Zea mays, Daucus
carota and Glycine max, Table 1, Online Supplementary Table S1). Oral delivery of several
plant-derived antigens has elicited antigen specific antibodies in mice and, in a few clinical
trials, in humans [13,14]. Vaccine antigens derived from enteric pathogens, such as Norwalk
virus capsid protein (NVCP), rotavirus capsid protein and the bacterial ganglioside-binding
protein cholera toxin B subunit (CTB) and Eschericia coli heat-labile toxin B subunit (LTB)
have been extensively evaluated in nuclear transgenic plants (Online Supplementary Table
S1). For example, mice orally immunized with carrot-derived LTB [15] or rice-derived CTB
[16] induce protection against cholera toxin (CT) challenge. Several other antigens from nonenteric pathogens such as F protein from respiratory syncytial virus [17] and surface antigen
from hepatitis B [18,19] also stimulate antigen-specific antibodies after oral delivery. However,
adjuvant might be required for such stimulation. For example, in the case of hepatitis B surface
antigen (HBsAg) fed to mice in transgenic potato tubers [20], it was necessary to use CT, a
potent mucosal adjuvant, to stimulate significant levels of anti-HBsAg antibodies, although
the same HBsAg potatoes fed to humans without adjuvant provoked serum anti-HBsAg in
most of the volunteers.
Given that potatoes and most other plant organs (except seeds) have a limited shelf life in the
fresh state, and vaccine dosage must be carefully monitored, it is unlikely that fresh,
unprocessed plant materials will be used as vaccines. Thus, some form of processing, such as
freeze-drying fruits or other plant organs, must be used to produce a product batch that can be
validated for potency and stability. For NVCP, it was demonstrated that either freeze or airdrying of transgenic tomato fruits yielded material that was at least as orally immunogenic as
fresh transgenic tomato [21]. However, freeze-dried potato NVCP produced poor results
compared with fresh potato NVCP [21], with oxidation of phenolic compounds in dried potato
probably causing the problem. Thus, control of oxidation will be an important issue when
tissues rich in phenolics and the enzyme polyphenol oxidase are used. The use of seed tissues
is more promising, and such material has demonstrated extended stability for both human and
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animal vaccine candidates. Seed-based vaccines are particularly attractive for the development
of veterinary products because of convenience in storage and delivery and have shown
promising results in farmed animal studies [22].

Transient expression with viral vectors

NIH-PA Author Manuscript

Development of a plant viral vector system for transient expression has enabled rapid
expression of recombinant proteins at levels higher than with stably integrated nuclear
transgenes (Table 1, Online Supplementary Table S1). Tobacco mosaic virus, although an RNA
virus that replicates in the cytosol, can be delivered as a DNA construct that is transcribed in
the nucleus to produce viral RNA. In one iteration, “magnIcon” technology has been used to
express hepatitis B core antigen [23], HbsAg [24], NVCP [25], and plague antigens F1 and V
[26] at levels of up to 1-2 mg g−1 fresh leaf mass in Nicotiana benthamiana, and in a similar
“Launch Vector” technology a range of candidates, including influenza targets, have been
expressed at high levels in N. benthamiana [27,28]. Given that tobacco or its close relatives,
such as N. benthamiana, are the usual hosts for this system, and vectors are generally introduced
by vacuum infiltration of Agrobacteria, the products must be purified for delivery as vaccines.
This ensures removal of any noxious host plant compounds and removal of Agrobacteria.
However, because purification is necessary, soluble antigens might lose oral immunogenicity
owing to the removal of the encapsulation effect that might help protect them from the harsh
stomach environment. Nonetheless, NVCP that was partially purified from leaves did induce
serum IgG and mucosal IgA responses after oral delivery to mice [25]. One approach that could
overcome this limitation is the expression of vaccine antigens as virus-like-particles. This has
been followed for a non-viral-based transient expression system, with promising
immunogenicity results following injection of purified influenza antigen [29]. This might be
extendable to oral delivery.

NIH-PA Author Manuscript

A further DNA replicon system was developed using the geminivirus bean yellow dwarf virus
(BeYDV) [30]. The construct is delivered by agro-infiltration, similar to the magnIcon and
launch vector systems. Similar to the launch vector system [27], it can be used as a single
vector, whereas the magnIcon system requires three separate vectors [25,26]. Expression of
HBcAg and NVCP in the range of 0.5-0.8 mg g−1 leaf mass was observed with the BeYDV
replicon, which is similar to that obtained with the magnIcon system. The magnIcon system
has also been adapted for IgG expression, but requires the combination of a TMV replicon with
a potato virus X (PVX) replicon [31], and five different Agrobacterium vectors. The BeYDV
replicon was also stably incorporated into the nuclear genome, with an inducible promoter
driving the viral Rep gene to control gene amplification [32]. Ten fold increases in expression
of NVCP in cultured tobacco cells were obtained after induction. This system might enable
the use of stable transgenic lines with improved expression.

Nuclear-derived pharmaceutical proteins
Recombinant pharmaceutical proteins are useful for treatment of various conditions, such as
genetic diseases that result in the production of an insufficient quantity or quality of a particular
protein. Given that many of these proteins would be administered parenterally, a high degree
of purification under current Good Manufacturing Practice (cGMP) conditions is necessary for
human use. Nuclear transgenic plant strategies have been used in many studies to demonstrate
the production of many valuable human proteins, including epidermal growth factor, serum
albumin, interferons, interleukins, lysozyme, lactoferrin and human acid β-glucosidase (Table
2, Online Supplementary Table S2). However, as with vaccine antigens, expression levels are
generally low. Specific assays demonstrated activity of the recombinant protein in vitro or in
cell-based assays, but extensive animal studies have not yet been published. Although plant
cells can synthesize and process mammalian proteins, in some cases, plant-specific
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glycosylation of ER- or cell surface-targeted proteins might produce undesired
immunogenicity of the recombinant protein, which could diminish its half-life and utility. βglucosidase produced in seeds of tobacco lacks the plant-specific xylose and fucose residues
that can be problematic [33]. If seed-based expression of other ER- or cell surface-targeted
proteins yields similar results, then targeting of recombinant proteins to seed storage vacuoles
will be an advantage. ER retention of proteins through the C-terminal inclusion of a KDEL or
KDEL-like tag serves to limit glycosylation of recombinant proteins to core glycan structures,
by comparison to cell surface-targeted proteins [4]. Also, recent advances in plant glycan
engineering hold the promise of broadly applicable production of pharmaceutical glycoproteins
in plants [34]. In addition, a few pharmaceutical proteins (human growth hormone, human
fibroblast growth factor, human diabetes-associated autoantigen etc.) have been produced in
plants using the transient expression system [35-37], where subcellular targeting is again an
option.

Chloroplast-derived vaccine antigens and therapeutics

NIH-PA Author Manuscript
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In chloroplast technology, foreign genes are integrated into the chloroplast genome by
homologous recombination [38], eliminating variation of expression among independent
transgenic lines. Moreover, gene silencing has not yet been reported in chloroplast transgenic
(transplastomic) lines. High levels of expression of vaccine antigens are facilitated by >10,000
copies of transgenes in each transformed plant cell. Chloroplast expression minimizes the risk
of foreign gene transfer via pollen from genetically modified crops to other related crops or
weeds owing to maternal inheritance of transgenes [39,40]. In addition, expression of
therapeutic proteins in leaves facilitates their harvest before the development of any
reproductive structures and offers additional opportunities for containment. Therefore, several
chloroplast-derived vaccine antigens and biopharmaceutical proteins have been grown in field
conditions and at least one such study has been published [41]. To date, 23 vaccines antigens
against 16 different diseases and 11 biopharmaceutical proteins have been expressed in
chloroplasts (Table 3, Online Supplementary Table S3). The presence of chaperones and posttranslational modification enzymes in the chloroplast creates a niche for target processing and
assembly with suitable post-translational modifications (assembly of multimers, disulfide
bonds, lipid modification, etc.), although glycosylation is not an option because Nglycosylation is not known to occur within chloroplasts. The chloroplast expression system
has been used to produce several fully functional vaccine antigens against bacterial, viral and
protozoan pathogens (Table 3, Online Supplementary Table S3). Proteins that are difficult to
express in other systems, such as antimicrobial proteins, have also been expressed in
chloroplasts [42,43]. In addition to plants, Chlamydomonas chloroplasts have been used for
expression of therapeutic proteins, although achieving higher levels of expression was a major
challenge until recent improvements in this system [44]. Indeed, adequate levels of expression
of therapeutic proteins in chloroplasts are not always possible and only a few proteins have
been evaluated for functionality (Table 3, Online Supplement Table S3).
One major limitation in this field is that several vaccine antigens and therapeutic proteins have
only been expressed in tobacco. Tobacco is not edible and the addictiveness of nicotine also
makes it unsuitable for oral delivery of therapeutic proteins. As an alternative, the carrot plastid
transformation system was developed with adequate levels of gene expression in edible tissues
to facilitate oral delivery [45]. However, carrot regeneration is slow and is not suitable for rapid
production of therapeutic proteins. Although adequate expression of HIV p24 antigen was
observed in tomato leaves [46], there was a >90% reduction in green fruits and no expression
was observed in ripe fruits. Lettuce (Lactuca sativa L.) chloroplast transformation has also
been developed [47-49] and there has been success in expressing the first therapeutic protein
(proinsulin) in lettuce chloroplasts [49]. Recently, this system has been optimized and several
therapeutic proteins have been expressed [3]. The level of expression in lettuce chloroplasts is
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similar to that in tobacco chloroplasts and regeneration is as rapid as in tobacco, thus opening
the door to practical oral delivery of chloroplast expressed proteins.
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Another challenge is oral delivery of chloroplast-derived proteins in adequate doses to confer
immunity or, in cases of autoantigens, to induce tolerance. In this context, it has been
demonstrated that chloroplast-derived therapeutic proteins, delivered orally via plant cells, are
protected from degradation in the stomach, presumably because of bio-encapsulation of the
antigen by the plant cell wall. To facilitate translocation of vaccine antigens or therapeutics
from the gut lumen into the circulatory system, target proteins have been fused to the CTB
trans-mucosal carrier protein, which can bind to the epithelial receptor GM1 [50]. This
approach has been widely applied to many orally delivered antigens, both for stable nuclear
transgenics and for transplastomic approaches.
Chloroplast-derived bacterial antigens

NIH-PA Author Manuscript

Several vaccine antigens against bacterial diseases have been produced in chloroplasts (Table
3, see Online Supplementary Table S3). CTB subunit [51,52], the first vaccine expressed in
chloroplasts, was shown to be functional by the GM1 binding assay. Subsequently, a fusion
of LTB and heat-stable toxin (ST) has been expressed in tobacco chloroplasts, and mice
immunized with a chloroplast-derived LTB-ST fusion protein were partly protected against
CT challenge [53]. Recently, two CTB fusion proteins were expressed in tobacco and lettuce
chloroplasts [3]. Both subcutaneously and orally administered mice with chloroplast-derived
CTB fusion proteins were protected against CT challenge. High levels of serum and intestinal
CTB-IgA were detected in orally administered mice. Although none of the mice administered
antigen subcutaneously had detectable CTB-IgA, high levels of IgG1 titer conferred protection
(86%) against the CT challenge. Comparable patterns of IgG1 expression observed in orally
administered mice in addition to intestinal and serum IgA conferred 100% protection and
confirmed that oral vaccination results in both a mucosal and a systemic immune response
[3]. Most importantly, long-term immunity and protection (up to 50% of mouse life span) was
observed. This is a significant advancement because immunity is lost in the current cholera
vaccine in children within 3 years and it is not fully protective in adults. Vaccine antigen against
tetanus also conferred complete protection against pathogen challenge [54]. Although
chloroplast-derived outer surface lipoprotein A (OspA) generated a lower level of protective
antibodies compared with lipidated Escherichia coli-derived OspA, the generated antibody
level could protect against Lyme disease [5].

NIH-PA Author Manuscript

The chloroplast transformation system has been used successfully to develop vaccines against
bioterrorism agents. The currently available anthrax vaccine obtained from the culture of
Bacillus anthracis has undesirable side effects, such as local pain and edema, and relatively
high rates of local and systemic reactions, including inflammation and flu-like symptoms. In
an attempt to produce anthrax vaccine in large quantities that is free of extraneous bacterial
contaminants, protective antigen (PA) was expressed in transgenic tobacco chloroplasts by
inserting the pagA gene into the chloroplast genome [55,56]. High levels of IgG titers have
been reported in mice immunized subcutaneously with partially purified chloroplast-derived
PA and 100% of animals survived against lethal doses of toxin challenge. It is estimated that
up to 360 million doses of fully functional anthrax vaccine could be produced from one acre
of tobacco [55,56].
By contrast, there is no approved vaccine for bubonic or pneumonic plague, which is a potential
agent for bioterrorism [57]. Recently, a plague F1-V fusion antigen has been expressed in
chloroplasts and its functionality was investigated in mice [58]. Animals immunized either
subcutaneously or orally with chloroplast-derived protective antigen F1-V showed
significantly higher levels of serum F1-V-specific IgG1 titers. Of the subcutaneously
immunized mice, 33% survived. By contrast, 88% of the orally immunized mice were protected
Trends Plant Sci. Author manuscript; available in PMC 2010 December 1.
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against a heavy dose of aerosolized Yesinia pestis plague challenge. A comparison of splenic
Y. pestis CFU counts showed up to a 10-log reduction in the mean bacterial burden in survivors.
This shows that oral delivery offers greater protection and immunity [58], and demonstrates
that oral delivery of a chloroplast-derived vaccine can be an effective mode of delivery for
plant-derived vaccine antigens.
Chloroplast-derived viral antigens
The first viral antigen capable of eliciting a protective immune response when expressed in
chloroplasts was against canine parvovirus (CPV) [52,59]. Mice immunized intraperitonially
with chloroplast-derived 2L21 fused to CTB in leaf extract elicited anti-2L21 antibodies.
Furthermore, the antibodies induced in rabbits by CTB-2L21-enriched plant extract efficiently
neutralized CPV infection of CRFK cells [59]. The structural protein E2, a neutralizing antigen
for classical swine fever virus (CSFV) was expressed in tobacco chloroplasts and subcutaneous
immunization induced serum antibody reaction against CSFV; however no immune response
was detected by oral immunization [60], in contrast to studies described above with F1-V.
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It has been shown that a chloroplast-derived subunit vaccine for hepatitis E virus ORF2encoded pE2 peptide induce pE2-specific antibody in subcutaneously immunized mice [61,
62]. Also, the major structural protein of human papillomavirus, HPV-16 capsid, L1 was
expressed from the tobacco chloroplast genome and the chloroplast-derived L1 protein
displayed conformation-specific epitopes and assembled into virus-like particles visible by
transmission electron microscopy [63,64]. Furthermore, chloroplast-derived L1 protein
showed immunogenic and neutralizing antibodies in mice injected intraperitonially [63].
Chloroplast-derived protozoan antigens
A potential anti-amoebic candidate, LecA, a surface antigen of E. histolytica, expressed in
tobacco chloroplasts, resulted in high immunogenicity in mice following subcutaneous
administration [65]. It has been reported that 29 million doses of vaccine antigen can be
produced per acre of transplastomic plants [65]. Recently, malarial vaccine candidates AMA1
and MSP1 fused with CTB were expressed in tobacco and lettuce chloroplasts, with a
significant level of antigen-specific titers in both oral and subcutaneously immunized mice
[3,66]. Immunoblot and immuno-fluorescence studies have shown that the chloroplast-derived
AMA1 and MSP1 inhibit the proliferation of the malarial parasite and cross-react with the
native parasite proteins at the schizont stage or ring trophozoite. In vitro parasite inhibition
studies show that mice with higher anti-MSP1 antibody titer exhibit the highest inhibition [3,
66].

NIH-PA Author Manuscript

Chloroplast-derived autoantigens
Type 1 diabetes (TD1) results from the autoimmune destruction of insulin-producing cells and
current treatments are not only expensive, but also provide only transient relief. Recently,
human proinsulin fused with CTB was expressed in lettuce and tobacco chloroplasts [49]. It
was shown that the pancreas of mice immunized with chloroplast-derived CTB-proinsulin had
decreased infiltration of cells characteristic of lymphocytes (insulitis) and significantly
preserved insulin-producing B-cells in the pancreatic islets with lower blood and urine glucose
levels. Moreover, increased expression of immunosuppressive cytokines, such as interleukin-4
and interleukin-10 (IL-4 and IL-10), was observed in the pancreas of chloroplast-derived CTBproinsulin treated mice, indicating T-helper 2 (Th2) lymphocyte-mediated oral tolerance
[49]. Another autoantigen for the prevention and delayed onset of TD1, glutamic acid
decarboxylase 65 (GAD65), has been expressed in Chlamydomonas chloroplasts and
recombinant hGAD65 reacted with TD1 sera from non-obese diabetic (NOD) mice and
stimulated the proliferation of spleen lymphocytes from these mice [67].
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Several chloroplast-derived pharmaceutical proteins have been produced (Table 3, Online
Supplementary Table S3). For example, human somatotropin (hST) was expressed in tobacco
chloroplasts and functionality was shown by using a rat lymphoma cell line, Nb2 proliferation
assay [68]. Human serum albumin expressed in tobacco chloroplasts formed inclusion bodies
[69]. Human interferon gamma (INF-γ) expressed in chloroplasts protected a human lung
carcinoma cell line against infection with the encephalomyocarditis (EMC) virus [70].
Chloroplast-derived IFN-α2b had similar activity to commercially produced PEG-Intron™,
protecting cells against cytopathic viral replication in the vesicular stomatitis virus cytopathic
effect (VSV CPE) assay, inhibiting early-stage human immune deficiency virus (HIV)
infection, and increasing the expression of major histocompatibility complex class I (MHC I)
on splenocytes and the total number of natural killer (NK) cells. IFN-α2b purified from
transplastomic lines protected mice from a highly metastatic tumor line following
intraperitoneal injection [41]. Human alpha1-antitrypsin (A1AT) expressed in tobacco
chloroplasts binds to porcine pancreatic elastase [71], although a detailed functional evaluation
is needed. Insulin-like growth factor 1 (IGF-1) was expressed in tobacco chloroplast [72]. Mass
spectrometry confirmed the identity of purified chloroplast-derived human IGF1. The
biological activity of the chloroplast-derived and the commercially synthesized human IGF-1
have similar levels of mitotic activity, as shown by a mammalian cell (human HU-3 cells)
proliferation assay [72]. Proper functionality of several of these human blood proteins show
that required disulfide bonds are formed in chloroplasts [41,68,70] Therefore, proper posttranslational modifications and functionally active chloroplast-derived therapeutic proteins
have opened the door for the production of low-cost plant based therapeutic proteins.

Conclusions
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When delivered orally, plant-derived vaccines and biopharmaceuticals have the advantage that
there is no need for expensive fermentation and purification systems and other expenses
associated with cold storage, transportation and sterile delivery. Although plant-made vaccines
have been developed and advanced for two decades, none of them have advanced beyond phase
I human clinical trials. Crucial evaluation of various expression systems highlights the
advantages and disadvantages of each system. Stable nuclear expression systems have been
developed over three decades and are available in a large number of crops, with the ability to
facilitate tissue-specific expression and inducible expression. However, as seen in the list of
vaccine antigens and biopharmaceuticals expressed via the nuclear genome (Online
Supplementary Tables S1,S2), expression levels are often inadequate for commercial
development, although adequately expressed antigens have advanced into clinical trials in a
few cases. Chloroplasts generally offer higher levels of expression of vaccine antigens against
bacterial, viral and protozoan pathogens and biopharmaceuticals, and transgene containment
via maternal inheritance. Chloroplast system for expression of therapeutic proteins has been
developed in the past eight years and recent development of an efficient lettuce chloroplast
system for oral delivery is a significant advancement. However, glycoproteins cannot be
expressed in chloroplasts in their glycosylated form. Although viral expression systems
produce therapeutic proteins quickly, they are generally not suitable for oral delivery [73].
Therefore, costs associated with purification, cold storage, transportation and sterile delivery
would be major challenge for the viral systems. The downsteam processing cost is typically
80% of the production cost and a significant challenge for the future is to reduce this [7].
However, research into the viral system has made significant progress recently, including the
development of an antibody for passive immunity against Non-Hodgkin's lymphoma in phase
I clinical trials [74], testing F1-V plague vaccine in monkeys [57] and the development of antiHIV peptides [75]. The transient expression technology is well suited for pandemic responses,
such as that faced with H1N1 influenza strains.
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The ultimate success of plant-based production systems for subunit vaccine and protein
therapeutic candidates is likely to depend on lead commercially viable targets successfully
transitioning through clinical trials over the next few years. Plant-based production systems
for recombinant proteins have been researched over the past 20 years, with a proliferation of
academic groups and biotechnology companies, together with groups from larger agrochemical
companies, developing the expression technologies and lead product candidates. This effort
needs to be repaid with positive results in later clinical studies for the field to continue to
advance. Notable early clinical stage successes have been recorded, advancing several oral (or
edible) vaccine candidates into Phase I trials [14,19,76-78]. However, none of these candidate
products have progressed further, largely because they either represented proof-of-principle
targets or impractical oral delivery vehicles. During the past five years, insufficient funding
and lack of commercial interest in plant-based oral vaccines has led to this approach slowing,
and no oral vaccine candidates have recently entered the clinic. The challenges of guiding novel
plant-based oral vaccines through the regulatory process currently outweigh available
resources. More recently, there has been an increased focus on using plant-based production
systems to generate purified recombinant proteins for vaccines and therapeutics to be delivered
by injection. Notable recent examples that have had clinical trial success include a personalized
therapeutic vaccine for non-Hodgkin's lymphoma assessed in a Phase I clinical trial [74], IFNα2b to combat hepatitis C assessed in a Phase IIa clinical trial (http://www.biolex.com), and
human glucocerebrosidase to combat Gaucher disease, which has now progressed into a Phase
III clinical trial [8]. These and similar purified protein products represent the current best
options for making plant-based production systems for human vaccines and therapeutics a
reality. In these cases, the emphasis is on demonstrating that the plant production systems can
generate antigen or therapeutic protein of comparable safety potency and efficacy to other
recombinant systems, without added concerns of an oral recombinant plant delivery vehicle.
On a parallel track, a plant-produced vaccine candidate for Newcastle disease in chickens was
approved for use in 2006. This again focused on a protein product purified from plant cells,
and emphasizes that plant-produced targets can progress along the regulatory path.
In summary, the availability of diverse plant-based production systems offers opportunities to
produce a wide array of antigens and biopharmaceutical proteins against diverse diseases, and
for different means of delivery to be explored. However, greater research emphasis is needed
on large scale production, purification, functional characterization, oral delivery and preclinical
evaluation for this field to move forward.
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Figure 1.

Schematic representation of vaccine antigens and biopharmaceuticals production in plants and
their functional evaluation in animal models. Explants are tissues that have the potential for
regeneration into mature plants. Here, we provide lettuce and tobacco as examples.
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Table 1

Recent vaccine antigens expressed via the plant nuclear genome that report immunogenicity or protection (for
full length table see Online Supplementary Table S1)

NIH-PA Author Manuscript

Antigen

NIH-PA Author Manuscript

Expression system

Expression level

Functional evaluation

Carrots

0.3% TSP

Immunogenic and protective against CT challenge [15]

Soybean

2.4% TSP

Tomato
Rice

0.081% TSP
2.1% TSP

Immunogenic and partial protection against LT
[4]
challenge in mice
Immunogenic by oral delivery to mice
[79]
Immunogenic and protective against CT challenge [16]
to mice following oral administration

Potato

8.5 μg g−1 FW

Hepatitis B virus surface antigen fused with
preS1 epitop
Human group A rotavirus (VP6) protein

Rice

31.5 ng g−1 DW

Alflfa

0.06-0.28% TSP

Rotavirus (VP7)

Potato tubers

0.3-0.4% TSP

Norwalk virus capsid protein

Tomato Fruit and Potato 8 and 0.4% TSP

SARS-CoV S protein (S1)
Smallpox recombinant vaccine virus B5
antigenic domain (pB5)
Japanese encephalitis virus (JEV) envelope
protein (E)
Protozoan antigens
Plasmodium yoelii merozoite surface protein
(PyMSP4/5)
Human vaccines (Viral/Transient expression)
Bacterial antigens
Yersinia pestis F1 and LcrV antigens

Tomato and tobacco leaf 0.1% TSP
Tobacco and Collard leafNot Reported

Yersinia pestis F1-V antigens

Tobacco leaf

Human vaccines (Stable expression)
Bacterial antigens
Enterotoxigenic E. coli Heat-labile toxin B
subunit (LTB)
Cholera toxin B subunit (CTB)
Viral antigens
Hepatistis B virus surface antigen

Refs

Immunogenic response in humans following oral [19]
administration
Immunogenic by intraperitoneal delivery to mice [80]
Immunogenic in mice and offspring developed less [81]
severe diarrhea after challenge with simian rotavirus
SA-11, indicating that antibodies generated in the
dams provided passive heterotypic protection to the
pups
Immunogenic in mice following oral delivery.
[82]
Neutralization activity against rotavirus
Elicit systemic and mucosal antibody responses in [21]
mice following oral administration
Immunogenic to mice following oral administration[83]
Antibody response in mice immunized parenterally [84]
and protects against lethal dose of vaccinia virus
JEV specific neutralizing antibody detected in mice[85]
following intraperitoneal or oral administration

Rice

1.1-1.9 μg mg−1 TSP

Tobacco

0.02-0.04% TSP

Tobacco leaf tissue

380 and 120 μg g−1 FWImmunogenic and protective in monkeys against Y. [57]
pestis following subcutaneous injection
1 and 2 mg g−1
Immunogenic and protection in vaccinated guinea [26]
pigs against Y. pestis aerosol challenge

Viral antigens
Smallpox recombinant vaccine virus B5
Tobacco leaf
antigenic domain (pB5)
Encoding domain III of the dengue 2 envelopeTobacco
protein (D2EIII)

Not Reported
0.28% TSP

HIV entry inhibitors red algal protein
griffithsin (GRFT)

Tobacco (TMV)

1 g kg−1 FW

Pathogenic avian influenza virus (H5N1
subtype)

Tobacco

60 mg kg−1

Induces antigen-specific antibodies in mice
following parenteral delivery

[86]

Antibody response in mice immunized perenterally [84]
and protective against lethal dose of vaccinia virus
Retains antigenicity and immunogenicity as well as[87]
inducing neutralizing antibodies in vaccinated
animals.
Active against HIV at picomolar concentrations, [75]
directly virucidal via binding to HIV envelope
glycoproteins and capable of blocking cell-to-cell
HIV transmission
Immunogenic in mice and ferret and also protects [28]
ferrets against challenge infection with virus
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Table 2

Biopharmaceutical proteins expressed via the plant nuclear genome (for full length table see Online
Supplementary Table S2)

NIH-PA Author Manuscript

Pharmaceutical protein
Human growth hormone (hGH)

Expression system Expression level
Rice suspension cells57 mg l−1

NIH-PA Author Manuscript

Functional evaluation
Refs
The biological activity of shGH accumulated in the transgenic[88]
rice cell suspension culture was similar to that of the E. coliderived recombinant hGH, as shown by proliferation of Nb2
node lymphoma cells
Mouse interleukin-12 (IL-12)
Tomato leaf and fruit2.7-7.3 and 1-3.4 μg g−1 FWBiologically active in vitro. The plant-produced mIL-12
[89]
induced the secretion of IFNγ by T cells
Human epidermal growth factor
Tobacco
0.09-0.3% TSP
Plant-produced hEGF significantly stimulated Vero E6 cell [90]
(hEGF)
expansion and proliferation similar to commercial hEGF
products
Human basic fibroblast growth factorSoybean
2.3% TSP
Mitogenic assay demonstrated that bFGF stimulated Balb/c [91]
(bFGF)
3T3 cells to proliferate in a dose-dependent manner, indicting
similar biological activity as native bFGF
Human acid β-glucosidase
Tobacco seeds
Not reported
Plant-derived GCase was taken up by fibroblasts of a Gaucher[33]
Type-II patient and lacks potentially immunogenic glycans
Human glucocerebrosidase enzyme Carrot cells
Not reported
Recombinant GCD in transgenic plant cells is biologically [8]
(GCD)
active. Phase I clinical trial have shown that no clinical or
laboratory evidence of any significant innate or humoral
immune reactions; and phase III clinical trial is currently
ongoing
Human cytokine granulocyte
Sugarcane
Undetectable-0.02% TSP Human bone marrow cells (TF-1), which require GM-CSF [92]
macrophage colony stimulating
for cell division, proliferated when growth media was
factor (GM-CSF)
supplemented with transgenic sugarcane extracts and had
identical activity levels
Human granulocyte-macrophage
Rice
1.2-1.3% TSP
Rice seed-derived hGMCSF induces proliferation of TF-1 [93]
colony stimulating factor (hGMcells similar to E. coli-derived hGM-CSF
CSF)
Macrophage colony-stimulating
Tobacco
0.02-1.92% TSP
Plant-derived M-CSFsR inhibits colony formation of J6-1 [94]
factor (M-CSF)1
cells
Human granulocyte-colony
Rice suspension cells0.7% TSP
Plant-derived hG-CSF supports proliferation of the
[95]
stimulating factor (hG-CSF)
AML-193 cells similar to commercial E. coli-derived hGCSF
Bone morphogenetic protein 2
Tobacco
0.02% TSP
Application of hBMP2 to mouse C2C12 cell line significantly[96]
(BMP2)
increased cell ALP activity but lower than commercial
rhBMP2
Human a-1-antitrypsin
Tomato
0.44-1.55% TSP
Biologically active, showing high specific activity and
[97]
efficient inhibition of elastase activity
Human IA-2 (IA-2ic), a diabetes- Tobacco (Transient) 0.5% TSP
Plant-derived IA-2ic protein is specifically recognized by [35]
associated autoantigen
human IA-2ic autoantibodies
Human fibroblast growth factor 8 Tobacco (Transient) 90-150 μg g−1 FW
Plant-expressed FGF8b effectively increased the rate of cell [36]
isoform b(FGF8b)
proliferation of NIH3T3 as bacterially expressed mouse
FGF8b

NIH-PA Author Manuscript
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Table 3

Functional vaccine antigens and biopharmaceutical proteins expressed via the chloroplast genome (for full length
table see Online Supplementary Table S3)

NIH-PA Author Manuscript

Vaccines antigens
Bacterial antigens
Cholera toxin B ( CtxB)

Expression system Expression level

Tetanus toxin ( TetC)

Tobacco

Anthrax protective antigen ( Pag)

Tobacco

Lyme disease –OspA (OspA, OspA-T)

Tobacco

Plague F1-V (CaF1-LcrV)

Tobacco

E. coli enterotoxin B (LTB)

Tobacco

Tobacco
Lettuce

NIH-PA Author Manuscript

Viral antigens
Canine parvovirus (CTB-2L21,GFP-2L21) Tobacco
Hepatitis E virus (HEV E2)
Tobacco
Leaves
Seeds
Swine fever virus (CSFV E2)
Human Papillomavirus (L1)

Tobacco
Tobacco

Protozoan antigens
Amoebiasis ( LecA)
Malaria (CTB-ama1 and CTB-msp1)

Tobacco
Tobacco
Lettuce
Tobacco
Lettuce

31.1 and 22.6% TSP

7% TSP
12.3% TSP
9.4% TSP
8% TSP
4.8% TSP

Chlamy

0.25-0.3% TSP

Tobacco LAMD
Petit Havana

8.0-21.0% TSP
2.0-14.0% TSP

NIH-PA Author Manuscript

Human alpha1-antitrypsin ( A1AT)
Tobacco
Antimicrobial peptide (2 lysin-type protein)Tobacco

Rabbit sera neutralized CPV in an in vitro assay
Immune response in mice

[59]
[62]

0.63-1.09 ng and
0.015-0.018 09 ng μg−1
TSP
1-2% TSP
Immune response in mice
[60]
20-26% TSP
Systemic immune response in mice after intraperitoneal [63]
injection, and neutralizing antibodies were detected

Tobacco and Lettuce~16% TSP
2.05-2.5% TSP

Insulin-like growth factor (IGF-1n, IGF-1s)Tobacco

Refs

4.1, 8 and 12.3% TSP GM1 ganglioside-binding assay. Long-term protection [3,66]
4.8 and 9.4% TSP
(50% mouse life span) against CT challenge in both oral
(100%) and subcutaneously (89%) immunized mice;
protection correlated with CTB-specific IgA and IgG1
titers in oral and IgG1 in subcutaneously immunized mice;
increasing numbers of IL10+ T-cell but not Foxp3+
regulatory T-cells, suppression of IFN-γ and absence of
IL-17 were observed in protected mice
18-27 and 7-10% TSP Mice developed systemic immune response and survived [54]
the tetanus toxin challenge
4.5-14.2% TSP
Macrophage lysis assay, systemic immune response, toxin [55]
neutralization assay, mice survived (100%) challenge
with lethal doses of toxin
1 and 10% TSP
Systemic immune response in mice. Protected mice
[5]
against Borrelia burgdorferi
14.8% TSP
Immunogenic in mice (IgG1 titers). Oral delivery offered [58]
greater protection (88%) and immunity than subcutaneous
(33%) injection when challenged with 50-fold lethal dose
of aerosolized Y. pestis
2.3% TSP
GM1 ganglioside-binding assay; oral immunization
[53]
partially protected mice from CT challenge

Autoantigens
Diabetes – Type 1 (CTB-pins)

Diabetes – Type 1 ( hGAD65)
Biopharmaceutical proteins
Interferon alpha 2b (IFNα2b)

Functional evaluation

32.4% TSP
32.7% TSP
2% TSP
~ 30% TSP

Systemic immune response in mice
[65]
Sera of immunized mice completely inhibited
[3,66]
proliferation of the malarial parasite and cross-reacted
with the native parasite proteins/parasites in immunoblots
and immuno-fluorescence studies, at the ring, trophozoite
or schizont parasite stages
CTB-prins treated mice showed significant decrease in [49]
inflammation (insulitis) in non-obese diabetic mice;
insulin-producing β -cells in the pancreatic islets of CTBPins-treated mice were highly protected, increase in
insulin production with lower blood or urine glucose
levels; Increased expression of immunosuppressive
cytokines (IL4, IL 10)
Immunoreactivity to diabetic sera
[67]
Immunogenic in mice. Transgenic IFN-a2b protected
[41]
baby hamster kidney cells against cytopathic viral
replication in vesicular stomatitis virus cytopathic effect
assay, HeLa cells from HIV-1 entry and mice from a
highly metastatic tumor line. Also, it increased the
expression of major histocompatibility complex class I on
splenocytes and the total number of natural killer cells
Growth response in cultured HU-3 cells
[72]
Fully active and binds to porcine pancreatic elastase
Bacteriolytic activity and kills Streptococcus
pneumoniae, the causative agent of pneumonia
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[71]
[43]

